<DOC>
	<DOC>NCT00415246</DOC>
	<brief_summary>To identify the proportion of patients remaining medically castrated (testosterone level &lt; 50 ng/dL) on Day 240 following two administrations of a 4-month sustained-release (SR) formulation of triptorelin.</brief_summary>
	<brief_title>Study to Evaluate a Subcutaneous Four Months Sustained-Release Formulation of Triptorelin in Patients With Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Triptorelin Pamoate</mesh_term>
	<criteria>Patient must give written (personally signed and dated) informed consent before completing any studyrelated procedure, which means any assessment or evaluation that would not have formed part of the normal medical care of the patient Patient must be 18 years old or over Patient must have a histologicallyconfirmed diagnosis of locally advanced or metastatic prostate cancer or presenting a relapse after curative treatment which is amenable to androgen deprivation therapy Patient must have an estimated survival time of greater than 8 months according to the investigator's assessment Patient at risk of a serious complication in the case of tumour flare (vertebral metastases threatening spinal cord compression or with significant obstructive uropathy) Patient who underwent a previous surgical castration Prostate cancer therapy within 2 months of baseline visit Patient with testosterone level below 150 ng/dL at screening</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2007</verification_date>
</DOC>